Clinico-Therapeutic Studies in Bovine Respiratory Disease Complex in Buffaloes

Praveen Kumar1*, Ashok Kumar2, Anup Yadav1, Umed Singh Mehra1, Rajendra Yadav3 and Pankaj Kumar4

1Department of Animal Husbandry and Dairying, Govt. of Haryana, India
2Department of Veterinary Medicine, College of Veterinary Sciences, LUVAS, Hisar, India
3Regional Veterinary Diagnostic and Extension Centre, Mahendergarh (LUVAS, Hisar), India
4Disease Investigation Laboratory, Rohtak (LUVAS, Hisar), India

*Corresponding author

A B S T R A C T

A study was carried out in 24 buffaloes affected with Bovine Respiratory Disease (BRD) Complex, which were diagnosed based on the history and clinical findings of inappetance to anorexia, fever, nasal discharge, coughing, dyspnoea and abnormal lung sounds on auscultation of thoracic area. The affected animals were randomly categorized in three groups for treatment to evaluate the therapeutic efficacy of ceftiofur, levofloxacin and moxifloxacin. Based on remission of clinical signs and symptoms ceftiofur was found to be most effective antibiotic for treatment of BRD complex in buffaloes.

Introduction

Respiratory diseases had notified a major impact on the overall health of bovines and continue to be of great importance even today. Many of the diseases that have been shown to impact the respiratory tract of cattle and buffaloes are grouped into an overall category known as bovine respiratory disease (BRD) complex. This includes shipping fever syndrome, mucosal disease, enzootic calf pneumonia, acute respiratory distress syndrome, haemorrhagic syndrome and atypical interstitial pneumonia (Apley, 2006). Bovine respiratory disease is a result of the complex interaction of bacterial and viral agents, environmental conditions, management factors and the animal health (Nickell and White, 2010). It is a major health problem of respiratory system occurring worldwide in both dairy and feedlot cattle (Edwards, 2010), responsible for high morbidity and mortality and has been reported to cause heavy economic losses in terms of drug and veterinary costs, extra labour and production losses (Gagea et al., 2006). These agents often produce mild clinical to severe clinical signs and death within 24 to 36 hours or may cause permanent lung damage as fibrosis, adhesions and/or abscesses, in chronic cases, which will impact performance. That is why early recognition and treatment of
BRDC are so important (Kirchhoff et al., 2014). Viral and bacterial agents proliferate, become pathogenic and damage the respiratory tract during the progression of subsequent respiratory disease (Panciera, 2010). The clinical signs of BRD complex vary according to the animal status, the level of stress that animal experiences, management practices and quantum of pathogen challenge (Smith, 2009; Snowder, 2009). The present study was undertaken to investigate the various clinical findings observed in buffaloes affected with BRD complex and to evaluate the therapeutic efficacy of ceftiofur, levofloxacin and moxifloxacin.

Materials and Methods

The study was conducted on 24 clinical cases of BRD complex in buffaloes which were reported at Teaching Veterinary Clinical Complex (TVCC), LalaLajpatRai University of Veterinary and Animal Sciences, Hisar (Haryana). A complete case history of affected animals was obtained from the animal’s owners and handlers. Eight apparently healthy buffaloes were also included in this study as control group. Thorough clinical examination of the suspected animals was made which included auscultation of thoracic area, recording of rectal body temperature, status of nasal discharge and coughing, respiratory rate and pattern, and mucus membranes. Gender wise all the affected animals were female belongs to different parities (1st to 6th parity) and aged ranging from 4 – 10 years. Animals having history and clinical symptoms of inappetance to anorexia, fever, nasal discharge, coughing, dyspnoea and abnormal lung sounds on auscultation were diagnosed to be suffered from BRD complex and considered for this study. To compare the therapeutic efficacy of ceftiofur, levofloxacin and moxifloxacin these 24 buffaloes affected with BRD complex were randomly categorized into three groups (group – I, II and III) with eight animals in each group. Ceftiofur @ 2.2 mg/kg body weight (group – I), levofloxacin @ 4 mg/kg body weight (group – II) and moxifloxacin @ 5 mg/kg body weight (group – III) was administered by intramuscular route once daily for 3 – 7 days depending on remission of clinical signs and symptoms. In addition to this, supportive therapy in the form of antihistaminics, non-steroidal anti-inflammatory drugs (NSAID), respiratory stimulants, liver extract, multivitamins and corticosteroids was given in recommended doses where warranted. Therapeutic efficacy of these three antibiotics was evaluated based on the remission of clinical signs and symptoms of BRD complex in affected animals and regaining of normal appetite during the course of treatment of 3 – 7 days.

Results and Discussion

Typically, diagnosis of BRD complex is based on a combination of objective (rectal body temperature, body weight) and subjective (depression, abnormal appetite and respiratory signs) assessments of affected animals, which is also concluded by many other researchers (Apley, 2006; Step et al., 2008; Patel et al., 2017; Arslan and Ozcan, 2018). Severity of clinical signs of BRD complex varies from unapparent to per-acute death as reported by Confer (2009) and Griffin et al., (2010). When clinical signs are observed, they are usually evident between 7 to 10 days after the stressful situation; however, in newly acquired buffalo, clinical signs can be present as late as 27 days after acquirement. This kind of findings was also observed in cattle by Zecchinon et al., (2005) and Griffin et al., (2010). During the course of this study the following clinical observations were made i.e. rectal body temperature, status of appetite (inappetence/anorexia), coughing, nasal discharge, dyspnoea and auscultation of thoracic area for abnormal lung sounds in all
animals included in this regime. Healthy control group animals were without any clinical signs. The mean±SE values of rectal body temperature of all the animals have been presented in table 1. Average body temperature of eight healthy animals kept in control group was 101.33±0.38 ºF. Animals of group I which were treated with ceftiofur had an average body temperature of 102.8±1.41 ºF on day 0 which after 3 days of treatment returned to near normal to 101.76±0.99 ºF followed by 101.76±0.99 ºF and 100.52±0.95 ºF on 5 and 7 days post treatment, respectively. The average body temperature of the animals treated with levofloxacin (Group – II) was 102.47±1.56 ºF on day 0, which returned to 101.91±1.01 ºF, 100.95±0.9 ºF and 100.48±0.57ºF on day 3, 5 and 7 post treatment, respectively. Moxifloxacin treated group animals (Group – III) showed the average body temperature as 103.08±0.88 ºF on day 0 which was later recorded as 102.43±0.6 ºF, 101.62±0.67 ºF and 100.82±0.46 ºF on 3, 5 and 7 days of post treatment, respectively.

The status of anorexia/inappetence was recorded on day 0 and post treatment days and has been presented in table 1. Control group animals were of normal appetite on day 0 while the animals of all the three groups affected with BRD complex were anorectic on the day of observation. In the ceftiofur treated animals, on day 3, three out of eight animals were anorectic and no animal was anorectic on day 5 of treatment. In levofloxacin treated group, all the animals were anorectic on day 3 while three out of eight animals were anorectic on day 5 and no animal was anorectic on day 7 of treatment. All the eight animals were anorectic in moxifloxacin treated group. On the day of observation (day 0) all the 24 affected buffaloes showing the clinical abnormalities in the form of coughing, nasal discharge, dyspnoea or abnormal auscultation findings in the thoracic area (Table 1). In the animals of groups treated with ceftiofur and levofloxacin it takes 5 and 7 days to get rid of these abnormal clinical findings, respectively. In the moxifloxacin treated group two out of eight animals were still showing the signs of coughing, nasal discharge, dyspnoea and abnormal auscultation findings even on day 7 of the treatment. In the present study, affected animals were showing high rectal temperature, anorexia/inappetance, coughing which varied in its duration, watery to serous type of nasal discharge and abnormal lung sounds such as crackles, wheezes, pleuritic frictional rubs etc. during the course of investigation. Similar types of findings were consistently observed by various other researchers (Zecchinon et al., 2005; Confer, 2009; Griffin et al., 2010; Ozkanlar et al., 2012; Urban – Chmiel and Grooms, 2012; Scott, 2013; Love et al., 2014) during their studies on respiratory tract diseases in animals. Depending on the severity of anorexia, animals can experience slight to severe weight loss. Similar findings were also observed by Zecchinon et al., (2005). The clinical expression of BRD complex varies according to the animal, the level of stress that animal experiences, management practices prior to and after the marketing process and level of pathogen challenge as also observed similarly by Snowder et al., 2006; Sanderson, 2008; Smith, 2009 and Snowder, 2009. Some scientists developed scoring systems based on the severity and duration of clinical signs and symptoms of BRD Complex (Perino and Apley, 1998 and Love et al., 2016) but these scoring systems had not found much importance in Indian scenario due to lack of well-organized farming practices as well as variable environmental and stress causing conditions.
Table.1 Clinical status of control and BRD complex affected buffaloes before and after treatment (n = 8 in each group)

| Group                              | Clinical Signs and Symptoms | Rectal Body Temperature (ºF) (Mean±SE) |
|------------------------------------|-----------------------------|---------------------------------------|
|                                    | Inappetence Anorexia | Coughing | Nasal Discharge | Dyspnoea | Abnormal Auscultation Findings |                                    |
| Control Group                      | No                         | No       | No             | No       | No                         | 101.33±0.38                        |
| Ceftiofur Treated Group (Group – I)| Day 0 8(+++)              | 8(+++)   | 7(+++)         | 6(+++)   | 7                          | 102.8±1.41                         |
|                                    | Day 3 3(+)                | 3(+)     | 3(++)          | 2(+)     | 2                          | 101.76±0.99                        |
|                                    | Day 5 0(-)                | 0(-)     | 0(-)           | 0(-)     | 0                          | 101.76±0.99                        |
|                                    | Day 7 0(-)                | 0(-)     | 0(-)           | 0(-)     | 0                          | 100.52±0.95                        |
| Levofloxacin Treated Group (Group – II)| Day 0 8(+++)              | 8(+++)   | 8(+++)         | 7(+++)   | 8                          | 102.47±1.56                        |
|                                    | Day 3 8(++)               | 6(++)    | 7(++)          | 6(++)    | 3                          | 101.91±1.01                        |
|                                    | Day 5 3(++)               | 1(+)     | 3(+)           | 2(+)     | 1                          | 100.95±0.9                          |
|                                    | Day 7 0(-)                | 0(-)     | 0(-)           | 0(-)     | 0                          | 100.48±0.57                        |
| Moxifloxacin Treated Group (Group – III)| Day 0 8(+++)              | 8(+++)   | 8(+++)         | 6(++)    | 8                          | 103.08±0.88                        |
|                                    | Day 3 8(++)               | 8(++)    | 8(++)          | 6(+)     | 5                          | 102.43±0.6                          |
|                                    | Day 5 6(++)               | 4(++)    | 6(++)          | 3(+)     | 3                          | 101.62±0.67                        |
|                                    | Day 7 2(+)                | 1(+)     | 1(+)           | 1(+)     | 2                          | 100.82±0.46                        |

+ Mild, ++ Moderate, +++ Severe, - Absent

The therapeutic regimen used in the present study comprised of three different antibiotics along with supportive measures, at times determined by clinical observations. Ceftiofur is a broad spectrum third-generation cephalosporin developed for the treatment of bovine respiratory disease (BRD) (Yancey et al., 1987) has demonstrated high in vitro activity against both Gram-positive and Gram-negative bacteria including bacterial pathogens associated with respiratory diseases (Hornish and Katarstsi, 2002). Levofloxacin is a second generation fluoroquinolone possesses excellent activity against Gram-positive, Gram negative and anaerobic bacteria (North et al., 1998). Moxifloxacin is a novel fourth generation fluoroquinolone with a broad spectrum antibacterial activity against Gram-positive, Gram-negative bacteria and anaerobes (Kowalski et al., 2003), and its lower MIC values and high serum and tissue concentration makes it a suitable antimicrobial for treating various infectious diseases including those of upper and lower respiratory tract (Blondeau and Hansen, 2001). In the present study, ceftiofur showed recovery in affected buffaloes in 3 days as evidenced by remission of clinical signs and symptoms while it was recorded in 5 days and 7 days after treatment with levofloxacin and moxifloxacin, respectively. Ceftiofur has also been previously used with god efficacy for the treatment of BRD complex by many researchers (Jim et al., 1992; Lockwood et al., 2003; Abutarbush et al., 2012 and Stegner et al., 2013). On the basis of remission clinical signs and symptoms (Inappetence/anorexia, coughing, nasal discharge, dyspnoea, abnormal auscultation findings and rectal body temperature), ceftiofur was found to be most effective antimicrobial for the treatment of BRD.
complex in buffaloes followed by levofloxacin and moxifloxacin.

In conclusion, BRD complex in buffaloes is still an important disease and will be serious problem for dairy industry in India for some more time because of its complex etiological structure and variability in therapeutic efficacy of various treatment regimens. Increasing antibiotic resistance to the pathogens is one of the negative parts of the situation; therefore treatment alternatives are getting decrease while treatment cost is increasing. In this frame, prevention and early diagnose of BRD based on clinical signs and symptoms have more importance for future of the dairy industry worldwide.

References

Abutarbush, S.M., Schunicht, O.C., Wildman, B.K., Hannon, S.J., Jim, G.K., Ward, T.I. and Booker, C.W. (2012). Comparison of enrofloxacin and ceftiofur sodium for the treatment of relapse of undifferentiated fever/bovine respiratory disease in feedlot cattle. *Canadian Vet. J.* 53: 57-62.

Apley, M. (2006). Bovine respiratory disease: Pathogenesis, clinical signs, and treatment in lightweight calves. *Vet. Clin. North Am. Food Anim. Pract.* 22(2): 399-411.

Arslan, H.H. and Ozcan, U. (2018). Current approach to bovine respiratory disease. *Dairy and Vet. Sci. J.* 5(2): 1-3.

Blondeau, J.M. and Hansen, G.T. (2001). Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. *Experimental Opinion Pharmacotherapy.* 2: 317–335.

Confer, A.W. (2009). Update on bacterial pathogenesis in BRD. *Anim. Health Res. Reviews.* 10(02): 145.

Edwards, T.A. (2010). Control methods for bovine respiratory disease for feedlot cattle. *Vet. Clin. North Am. Food Anim. Pract.* 26: 273–284.

Gagea, M.I., Bateman, K.G. and van Dreumel T. (2006). Diseases and pathogens associated with mortality in Ontario beef feedlots. *J. Vet. Diagn. Invest.* 18: 18–28.

Griffin, D., Chengappa, M.M., Kuszak, J. and McVey, D.S. (2010). Bacterial pathogens of the bovine respiratory disease complex. *Vet. Clin. North Am. Food Anim. Pract.* 26(2): 381-394.

Hornish, R.E. and Katarski, S.F. (2002). Cephalosporins in veterinary medicine – Ceftiofur use in food animals. *Current Topics in Medicinal Chemistry.* 2: 717-731.

Jim, K.G., Booker, C.W. and Guichon, P.W. (1992). A comparison of trimethoprim-sulfadoxine and ceftiofur sodium for the treatment of respiratory disease in feedlot calves. *Canadian Vet. J.* 33: 245-250.

Kirchhoff, J., Uhlenbruck, S., Goris, K.M., Keil, G. and Herrler, G. (2014). Three viruses of the bovine respiratory disease complex apply different strategies to initiate infection. *Vet. Res.* 45(1): 20-25.

Kowalski, R.P., Dhaliwal, D.K., Karenchak, L.M., Romanowski, E.G., Mah, F.S., Ritterband, D.C. and Gordon, Y.J. (2003). Gatifloxacin and moxifloxacin: an *in vitro* susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. *American J. Ophtha.* 136: 500–505.

Lockwood, P.W., Johnson, J.C. and Katz, T.L. (2003). Clinical efficacy of flunixin, carprofen and ketoprofen as adjuncts to the antibacterial treatment of bovine respiratory disease. *Vet. Rec.* 152: 392-394.

Love, W.J., Lehenbauer, T.W., Kass, P.H., Van Eenennaam, A.L. and Aly, S.S. (2014). Development of a novel clinical scoring system for on-farm diagnosis of bovine respiratory disease in pre-weaned dairy calves. *Peer Review J.* 238: 1-25.

Love, W.J., Lehenbauer, T.W., Kass, P.H., Van Eenennaam, A.L., Drake, C.M., Farver, T.B. and Aly, S.S. (2016). Sensitivity and specificity of on-farm scoring systems and nasal culture to detect bovine respiratory disease complex in pre-
weaned dairy calves. *J. Vet. Diagn. Invest.* 28(2): 119–128.

Nickell, J.S. and White, B.J. (2010). Metaphylactic antimicrobial therapy for bovine respiratory disease in stocker and feedlot cattle. *Vet. Clin. North Am. Food Anim. Pract.* 26(2): 285-301.

North, D.S., Fish, D.N. and Redington J.J. (1998). Levofloxacin, a second generation fluoroquinolone. *Pharmacotherapy.* 18: 915-935.

Ozkanlar, P., Aktas, M.S., Kaynar, O., Ozkanlar, S., Kirecci, E. and Yildiz, L. (2012). Bovine respiratory disease in naturally infected calves: clinical signs, blood gases and cytokine response. *Rev. Med. Vet.* 163(3): 123-130.

Panciera, R.J. (2010). Pathogenesis and pathology of bovine pneumonia. *Vet. Clin. North Am. Food Anim. Pract.* 26(2): 191.

Patel, N., Patel, R.K., Rajoriya, J.S., Ahirwaar, M.K., Hari, R. and Ojha, B.K. (2017). Bovine respiratory disease complex: A critical review. *Int. J. Livestock Res.* 7(7): 23-34.

Perino, L.J. and Apley, M.D. (1998). Clinical trial design in feedlots. *Vet. Clinics: Food Anim. Pract.* 14: 343–365.

Sanderson, M.W. (2008). Risk factors for initial respiratory disease in United States feedlots based on producer-collected daily morbidity counts. *Canadian Vet. J.* 49(4): 373.

Scott, P.R. (2013). Clinical presentation, auscultation recordings, ultrasonographic findings and treatment response of 12 adult cattle with chronic suppurative pneumonia: case study. *Irish Vet. J.* 66: 5.

Smith, R.A. (2009). North American cattle marketing and bovine respiratory disease (BRD). *Anim. Health Res. Reviews.* 10(02): 105.

Snowder, G. (2009). Genetics, environment and bovine respiratory disease. *Anim. Health Res. Reviews.* 10(02): 117.

Snowder, G.D., Van Vleck, L.D., Cundiff, L.V. and Bennett, G.L. (2006). Bovine respiratory disease in feedlot cattle: Environmental, genetic, and economic factors. *J. Anim. Sci.* 84(8): 1999-2008.

Stegner, J.E., Lucas, M.J., McLaughlin, C.L., Davis, M.S., Alaniz, G.R., Weigel, D.J., Pollreisz, J.H., Tucker, C.M., Koers, W.C., Turgeon, O.A. and Szasz, J.I. (2013). Comparative effects of therapeutic programs on bovine respiratory disease, performance, carcass, and profitability of high-risk feedlot heifers. *The Professional Animal Scientist.* 29: 208–218.

Step, D.L., Krehbiel, C.R. and DePra, H.A. (2008). Effects of commingling beef calves from different sources and weaning protocols during a forty-two-day receiving period on performance and bovine respiratory disease. *J. Anim. Sci.* 86(11): 3146-3158.

Urban – Chmiel, R. and Grooms, D.L. (2012). Prevention and Control of Bovine Respiratory Disease. *J. Livestock Sci.* 3: 27-36.

Yancey, R.J., Jr., Kinney, M.L. and Roberts, B.J. (1987). Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice. *Am. J. Vet. Res.* 7: 1050-1053.

Zecchinon, L., Fett, T. and Desmecht, D. (2005). How *Mannheimia haemolytica* defeats host defence through a kiss of death mechanism. *Vet. Res.* 36(2): 133-156.

How to cite this article:

Praveen Kumar, Ashok Kumar, Anup Yadav, Umed Singh Mehra, Rajendra Yadav and Pankaj Kumar. 2018. Clinico-Therapeutic Studies in Bovine Respiratory Disease Complex in Buffaloes. *Int. J. Curr. Microbiol. App. Sci.* 7(11): 2042-2047. doi: https://doi.org/10.20546/ijcmas.2018.711.232